EXEL - Exelixis, Inc. Stock Analysis

Stock Taper

SCREENER COMPARE ANY 2 STOCKS

EXEL

EXELIXIS, INC.

NASDAQ

$54.45

▼ DOWN 1.47% (-0.81)

KEY STATISTICS

Market Cap$13.69 B

52w High$57.57

52w Low$33.76

Dividend Yield—

Frequency—

P/E15.56

Volume1.49M

Shares Out.251.36M

COMPANY

LEADERSHIP

CHIEF EXECUTIVE

Michael Morrissey

COMPENSATION 2026

Salary$1,306,040

Stock Awards$30,539,552

Incentive Plan Pay$1,382,591

All Other Comp.$11,000

Total$33,239,183

ABOUT

SECTOR

Healthcare

WENT PUBLIC

April 17, 2000

METHOD OF GOING PUBLIC

IPO

FULL TIME EMPLOYEES

1,077

PRICE TARGET

Target High$56.00

Target Low$46.00

Target Median$52.00

Target Consensus$51.78

UPCOMING EARNINGS

DateNov 3, 2026

DayTuesday

Rev. Est.$650.29M

NOV

TUE

PRICE

$54.45 ▼ DOWN 1.47% (−$0.81)

About Exelixis, Inc.

https://www.exelixis.com ↗

Exelixis, Inc. is an oncology biotech developing and commercializing cancer medicines like CABOMETYX and COMETRIQ, with a pipeline including kinase inhibitors and antibody-drug conjugates, collaborating globally to advance cancer treatments.

INDUSTRY

Biotechnology

A PRODUCT EXELIXIS, INC. IS KNOWN FOR

CABOMETYX® (cabozantinib)

CABOMETYX is an oral kinase inhibitor by Exelixis for treating advanced renal, liver, and thyroid cancers, playing a key role in the company's oncology portfolio and revenue.

COMPETITORS

COMPETITOR

Revenue by Products

PRODUCT	Q2-2025	Q4-2025	Q1-2026	Q2-2026
Product Gross	$745.28M	$1.54B ▲	$795.35M ▼	$812.78M ▲
Product	$520.01M	$1.09B ▲	$554.98M ▼	$573.02M ▲
License	$49.3M	$122.59M ▲	$56.95M ▼	$59.81M ▲
Collaboration	$48.25M	$106.91M ▲	$55.84M ▼	$55.66M ▼
Service	-$1.05M	$0 ▲	-$1.11M ▼	-$4.14M ▼
Product Sales Discounts And Allowances	-$225.27M	$0 ▲	-$240.38M ▼	-$239.76M ▲